Your browser doesn't support javascript.
loading
Suicidal ideation among people with Parkinson's disease and comparison with a control group.
Santos-García, Diego; de Deus Fonticoba, Teresa; Cores Bartolomé, Carlos; Feal Panceiras, Maria J; García Díaz, Iago; Íñiguez Alvarado, Maria Cristina; Jesús, Silvia; Boungiorno, Maria Teresa; Planellas, Lluís; Cosgaya, Marina; García Caldentey, Juan; Caballol, Nuria; Legarda, Ines; Hernández Vara, Jorge; Cabo, Iria; López Manzanares, Lydia; González Aramburu, Isabel; Ávila Rivera, Maria A; Gómez Mayordomo, Víctor; Nogueira, Víctor; Puente, Víctor; Dotor García-Soto, Julio; Borrué, Carmen; Vila, Berta Solano; Álvarez Sauco, María; Vela, Lydia; Escalante, Sonia; Cubo, Esther; Carrillo Padilla, Francisco; Martínez Castrillo, Juan C; Sánchez Alonso, Pilar; Alonso Losada, Maria G; López Ariztegui, Nuria; Gastón, Itziar; Kulisevsky, Jaime; Blázquez Estrada, Marta; Seijo, Manuel; Rúiz Martínez, Javier; Valero, Caridad; Kurtis, Mónica; de Fábregues, Oriol; González Ardura, Jessica; Alonso Redondo, Ruben; Ordás, Carlos; López Díaz, Luis M; McAfee, Darrian; Martinez-Martin, Pablo; Mir, Pablo.
Affiliation
  • Santos-García D; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • de Deus Fonticoba T; CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
  • Cores Bartolomé C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Feal Panceiras MJ; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • García Díaz I; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Íñiguez Alvarado MC; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Jesús S; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Boungiorno MT; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Planellas L; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.
  • Cosgaya M; Clínica del Pilar, Barcelona, Spain.
  • García Caldentey J; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Caballol N; Centro Neurológico Oms 42, Palma de Mallorca, Spain.
  • Legarda I; Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
  • Hernández Vara J; Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Cabo I; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • López Manzanares L; Hospital Universitario Vall d´Hebron, Barcelona, Spain.
  • González Aramburu I; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • Ávila Rivera MA; Hospital Universitario La Princesa, Madrid, Spain.
  • Gómez Mayordomo V; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Nogueira V; Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Puente V; Consorci Sanitari Integral, Hospital General de L´Hospitalet, L´Hospitalet de Llobregat, Barcelona, Spain.
  • Dotor García-Soto J; Neurology Department, Institute of Neuroscience, Vithas Madrid La Milagrosa University Hospital, Vithas Hospital Group, Madrid, Spain.
  • Borrué C; Hospital Da Costa, Burela, Lugo, Spain.
  • Vila BS; Hospital del Mar, Barcelona, Spain.
  • Álvarez Sauco M; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Vela L; Hospital Infanta Sofía, Madrid, Spain.
  • Escalante S; Institut d'Assistència Sanitària (IAS) - Institut Català de la Salut, Girona, Spain.
  • Cubo E; Hospital General Universitario de Elche, Elche, Spain.
  • Carrillo Padilla F; Fundación Hospital de Alcorcón, Madrid, Spain.
  • Martínez Castrillo JC; Hospital de Tortosa Verge de La Cinta (HTVC), Tortosa, Tarragona, Spain.
  • Sánchez Alonso P; Complejo Asistencial Universitario de Burgos, Burgos, Spain.
  • Alonso Losada MG; Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.
  • López Ariztegui N; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Gastón I; Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Kulisevsky J; Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
  • Blázquez Estrada M; Complejo Hospitalario de Toledo, Toledo, Spain.
  • Seijo M; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Rúiz Martínez J; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Valero C; Hospital de Sant Pau, Barcelona, Spain.
  • Kurtis M; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • de Fábregues O; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • González Ardura J; Hospital Universitario Donostia, San Sebastián, Spain.
  • Alonso Redondo R; Hospital Arnau de Vilanova, Valencia, Spain.
  • Ordás C; Hospital Ruber Internacional, Madrid, Spain.
  • López Díaz LM; Hospital Universitario Vall d´Hebron, Barcelona, Spain.
  • McAfee D; Hospital de Cabueñes, Gijón, Spain.
  • Martinez-Martin P; Universitario Lucus Augusti (HULA), Lugo, Spain.
  • Mir P; Hospital Rey Juan Carlos, Madrid, Spain.
Int J Geriatr Psychiatry ; 38(5): e5919, 2023 05.
Article in En | MEDLINE | ID: mdl-37147900
ABSTRACT

BACKGROUND:

Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group.

METHODS:

PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted V0 (baseline); V2 (2-year ± 1 month follow-up). SI was defined as a score ≥1 on item nine of the Beck Depression Inventory-II (BDI-II). Regression analyses were conducted to identify factors related to SI.

RESULTS:

At baseline, 693 PwPD (60.2% males; 62.59 ± 8.91 years old) and 207 controls (49.8% males; 60.99 ± 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041).

CONCLUSION:

The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Depressive Disorder, Major Type of study: Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Int J Geriatr Psychiatry Journal subject: GERIATRIA / PSIQUIATRIA Year: 2023 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Depressive Disorder, Major Type of study: Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Int J Geriatr Psychiatry Journal subject: GERIATRIA / PSIQUIATRIA Year: 2023 Type: Article Affiliation country: Spain